Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.

Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, Antunes AS, Oehme I, Pekrun A, Pfister SM, Kulozik AE, Witt O, Deubzer HE.

J Neurooncol. 2012 Dec;110(3):335-48. doi: 10.1007/s11060-012-0978-1. Epub 2012 Oct 6.

PMID:
23054560
2.

Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.

Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, Blaney SM, Lau CC, Li XN.

Clin Cancer Res. 2006 Aug 1;12(15):4687-94. Erratum in: Clin Cancer Res. 2012 Apr 1;18(7):2116.

3.

Overexpressed TP73 induces apoptosis in medulloblastoma.

Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JY.

BMC Cancer. 2007 Jul 12;7:127.

4.

Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.

Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ.

J Clin Oncol. 2006 Apr 20;24(12):1924-31. Epub 2006 Mar 27.

PMID:
16567768
5.

Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization.

Tong CY, Hui AB, Yin XL, Pang JC, Zhu XL, Poon WS, Ng HK.

J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):187-93.

PMID:
14758948
6.

miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.

Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, Cho YJ.

Neuro Oncol. 2011 Feb;13(2):165-75. doi: 10.1093/neuonc/noq179. Epub 2010 Dec 22.

7.

Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.

Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC.

J Clin Oncol. 2011 Apr 10;29(11):1400-7. doi: 10.1200/JCO.2010.30.2810. Epub 2010 Oct 4.

8.

Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature.

Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, Scheithauer BW, Jenkins RB.

Clin Neurol Neurosurg. 2000 Dec;102(4):203-209. Review.

PMID:
11154805
9.

In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line.

Wen DY, Hall WA, Conrad J, Godal A, Flørenes VA, Fodstad O.

Neurosurgery. 1995 Jun;36(6):1158-63; discussion 1163-4.

PMID:
7643997
10.

Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.

DeChiara C, Borghese A, Fiorillo A, Genesio R, Conti A, D'Amore R, Pettinato G, Varone A, Maggi G.

Childs Nerv Syst. 2002 Aug;18(8):380-4. Epub 2002 Jul 27.

PMID:
12192498
11.

Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.

Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC.

J Neuropathol Exp Neurol. 2004 May;63(5):441-9.

PMID:
15198123
12.

Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.

Faria CC, Golbourn BJ, Dubuc AM, Remke M, Diaz RJ, Agnihotri S, Luck A, Sabha N, Olsen S, Wu X, Garzia L, Ramaswamy V, Mack SC, Wang X, Leadley M, Reynaud D, Ermini L, Post M, Northcott PA, Pfister SM, Croul SE, Kool M, Korshunov A, Smith CA, Taylor MD, Rutka JT.

Cancer Res. 2015 Jan 1;75(1):134-46. doi: 10.1158/0008-5472.CAN-13-3629. Epub 2014 Nov 12.

14.

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.

Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R.

PLoS One. 2008 Aug 28;3(8):e3088. doi: 10.1371/journal.pone.0003088.

15.

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.

Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH.

Oncotarget. 2013 Nov;4(11):2080-95.

16.

Expression patterns and potential roles of SIRT1 in human medulloblastoma cells in vivo and in vitro.

Ma JX, Li H, Chen XM, Yang XH, Wang Q, Wu ML, Kong QY, Li ZX, Liu J.

Neuropathology. 2013 Feb;33(1):7-16. doi: 10.1111/j.1440-1789.2012.01318.x. Epub 2012 Apr 27.

PMID:
22537175
17.

The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.

Kumar A, Fillmore HL, Kadian R, Broaddus WC, Tye GW, Van Meter TE.

Mol Cancer Res. 2009 Nov;7(11):1813-21. doi: 10.1158/1541-7786.MCR-09-0069. Epub 2009 Nov 3.

18.

A mouse model of the most aggressive subgroup of human medulloblastoma.

Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao C, Finkelstein D, Qu C, Pounds S, Ellison DW, Gilbertson RJ, Roussel MF.

Cancer Cell. 2012 Feb 14;21(2):168-80. doi: 10.1016/j.ccr.2011.12.023.

19.

Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2.

Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC.

Neuro Oncol. 2008 Dec;10(6):981-94. doi: 10.1215/15228517-2008-048. Epub 2008 Jul 29.

20.

"Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.

Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, Kun LE, Goldthwaite PT, Burger PC.

J Neuropathol Exp Neurol. 2000 Oct;59(10):857-65.

PMID:
11079775

Supplemental Content

Support Center